Accelerate Drug Development With Innovative 360˚ CDMO And CRO Solutions

Pharmaceutical companies are under increasing pressure to deliver therapies faster while managing rising development costs, extended timelines, and greater regulatory complexity. Thermo Fisher Scientific’s Accelerator™ Drug Development is designed to address these challenges through a fully integrated 360° CDMO and CRO approach that helps Sponsors streamline development, reduce risk, and improve speed to market.
By combining scientific expertise, advanced technologies, and end-to-end development capabilities, Accelerator™ Drug Development supports programs from early discovery through clinical development and commercialization. This integrated model enables better decision-making, stronger cross-functional collaboration, and more efficient execution across the drug development lifecycle.
Key areas of focus include:
-
Integrated development solutions: Coordinated CDMO and CRO services that simplify program management and improve continuity across development stages.
-
Right-first-time strategies: Approaches that help reduce rework, minimize delays, and improve development efficiency.
-
Scalability and risk reduction: Proven processes and technical expertise that support smooth transitions from development to manufacturing and commercialization.
-
Regulatory and operational excellence: Insights into navigating regulatory challenges while maintaining quality, compliance, and supply chain reliability.
-
Real-world impact: Examples demonstrating how integrated partnerships can accelerate timelines, enhance scalability, and help bring innovative therapies to patients sooner.
Accelerator™ Drug Development provides a strategic, end-to-end partnership model that helps Sponsors optimize resources, overcome development challenges, and advance promising therapies with greater confidence and efficiency.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Supply Leader? Subscribe today.